ABL1 and acute lymphoblastic leukemia: Ponatinib is one of a newer generation of TKIs and has potent activity in both wild-type BCR/ABL1-positive ALL and mutant forms (e.g., with the gatekeeper mutation ABL1 T315I) [40].